Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected. Approximately, 77% of all types United States. A total of ? 1,399,790 new of cancers are diagnosed in persons of 55 cancer cases and ? 564,830 deaths were years and older. It was estimated that o- reported in the year 2006 in the country. third of the 559,650 cancer deaths in 2007 Approximately, one in every two men and in the United States were related to ov- one in every three women in the country weight or obesity, physical inactivity, and will have some type of cancer during nutrition, and thus could also be prevented their lifetime. Healthcare costs exceed (Am. Cancer Society, 2007). However, 1. 7 trillion dollars per year in the United in developed countries, including United States, which is ? 15% of the country’s States, the average person of 65 years can gross domestic product. expect to live another 15 years in a fairly Tobacco use is the most serious prevent- good health. Persons of 75 or 85 years old able cause of cancer. Tobacco use causes have an average expectancy of 10 and 6 cancer of the lung, throat, mouth, pancreas, years, respectively. urinary bladder, stomach, liver, kidney, and During the last three decades, intensive other types. Passive smoking causes lung clinical research has resulted in reduced cancer.
Les mer
Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected.
General Methods and Overviews.- Metabolic Transformations of Malignant Cells: An Overview.- Detection of Recurrent Cancer by Radiological Imaging.- Tumor Gene Therapy: Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy.- Assessment of Gene Transfer: Magnetic Resonance Imaging and Nuclear Medicine Techniques.- Role of TP53 Mutations in Cancer (An Overview).- Personalized Medicine for Cancer.- Radiation Doses to Patients Using Computed Radiography, Direct Digital Radiography, and Screen-Film Radiography.- Cancer Vaccines and Immune Monitoring (An Overview).- New Insights into the Role of Infection,Immunity and Apoptosis in the Genesis of the Cancer Stem Cell.- Successful Cancer Treatment: Eradication of Cancer Stem Cells.- Overexposure of Patients to Ionizing Radiation: An Overview.- Lung Cancer.- Lung Carcinoma.- Extra-Pulmonary Small Cell Cancer: Diagnosis, Treatment, and Prognosis.- Magnetic Resonance Imaging of the Lung: Automated Segmentation Methods.- Peripheral Lung Lesions: Diagnosis Using Transcutaneous Contrast-Enhanced Sonography.- Small Pulmonary Nodules: Detection Using Multidetector-Row Computed Tomography.- Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer.- Advanced Non-Small Cell Lung Cancer: Second-Line Treatment with Docetaxel.- Non-Small Cell Lung Cancer with Brain Metastases: Platinum-Based Chemotherapy.- Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib.- Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib.- Prognostic Significance of [18F]-Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Pathological Stage I Lung Adenocarcinoma.- Non-Small Cell Lung Cancer: Prognosis Using the TNM Staging System.- Differentiation Between Malignant andBenign Pleural Effusions: Methylation Specific Polymerase Chain Reaction Analysis.- Pathological Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small-Cell Lung Carcinoma Using Immunohistochemistry.- Differentiation Between Pleuropulmonary Desmoid Tumors and Solitary Fibrous Tumors: Role of Histology and Immunohistochemistry.- Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation.- Prostate Cancer.- Prostate Carcinoma.- The Role of Intermediary Metabolism and Molecular Genetics in Prostate Cancer.- Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications.- Prostate Cancer: Role of Vav3 Overexpression in Development and Progression.- Prostate Cancer: Detection and Monitoring Using Mitochondrial Mutations as a Biomarker.- Prognostic Markers in Prostatic Carcinoma.- Prostate Cancer: Detection of Free Tumor-Specific DNA in Blood and Bone Marrow.- Prostate Carcinoma: Evaluation Using Transrectal Sonography.- Prostate Cancer: 16?-[18F] Fluoro-5?-Dihydrotesterone (FDHT) Whole-Body Positron Emission Tomography.- Effects of Standard Treatments on the Immune Response to Prostate Cancer.- Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer.- Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy.
Les mer
This is the first book that discusses the subjects of diagnosis, therapy, therapy assessment, and prognosis of lung and prostate cancer in one single volume. Cancer killed 6.7 million people around the world in 2002, and this figure is expected to rise to 10.1 million in 2020. Lung cancer has been the most common cancer in the world since 1985, and by 2002 there were 1.35 million new cases, representing 12.5% of all new cancers. It was also the most common cause of death from cancer, with 1.18 million deaths (17.6% of the world total). Lung cancer remains a highly lethal disease. After diagnosis, survival at 5 years in the United States is 15%. This second volume in the series Methods of Cancer Diagnosis, Therapy and Prognosis presents a comprehensive treatise on all aspects of Lung and Prostate cancer, including diagnosis, treatments and prognosis. Scientists and Clinicians have contributed state of the art chapters on their respective areas of expertise providing the reader a whole field view of lung and prostate cancer management. This fully illustrated volume  * Discusses diagnosis using molecular genetics, various imaging modalities, tumor markers and tumor gene therapy  * Discusses treatments such as chemotherapy, radiation, chemoradiation, hormonal therapy, immunotherapy, and surgery; and prognosis * Highlights both primary and secondary cancers, and explains the risk of cancer survivors developing other cancers. * Attempts to translate molecular genetics into clinical practice. Evidence-based therapy is included.  * Discusses the role of histology and immunohistochemistry in differentiating between pleuropulmonary desmoid tumors and solid fibroustumors. * Discusses cancer stem cells, mutations, cancer vaccines, and personalized cancer medicine. Professor Hayat has summarized the problems associated with the complexities of research publications and has been successful in editinga must-read volume for oncologists, cancer researchers, medical teachers and students of cancer biology.
Les mer
"Once more Professor Hayat has to be congratulated for bringing together 56 leading scientists representing 16 countries in the field of breast cancer, which has made it possible to publish such an excellent book. It represents a valuable addition to the available literature on breast cancer treatment since it covers all aspects of breast cancer, including diagnosis, treatments, and prognosis. Thereby, not only efficacy of various anticancer drugs and their side-effects are pointed out, but also the necessity of age-dependent breast cancer strategies is highlighted. Therefore, I conclude that this book is a true benefit to all clinicians, surgeons, and oncologists working in the field of breast cancer." Professor Dr. Thomas DittmerInstitute of ImmunologyWitten/Herdecke UniversityWitten, Germany "This first volume of the Handbook on Methods of Cancer Diagnosis, Therapy, and Prognosis, concerns problems related to diagnosis, treatment, monitoring of therapy, and prognosis in breast cancer. This is an impressive monograph containing data range on novel techniques (e.g., PET examination of sentinel lymph nodes) used in early diagnosis, prognosis (Molecular studies on circulating neoplastic cells), and treatment (surgery, chemo-radio-and hormontherapy) of various histological types of breast cancer. This monograph resulting from cooperative efforts of 56 authors from 16 countries (specialists in this field) cannot be matched by any publication of this type. The oncologists, pathologists, and scientists engaged in problems of breast cancer should have this extremely valuable Handbook at hand." Professor Piotr DziegielDepartment of Histology and EmbryologyMedical University of Wroclaw, Poland "It has been a great pleasure to review the forthcoming book, Methods of Cancer Diagnosis, Therapy, and Prognosis: Volume 1, edited by Professor M.A. Hayat. Dr. Hayat is a Distinguished Professor in the Department of Biological Sciences, Kean University, Union, New Jersey. After seeing the chapters listed in his book, I am very impressed by the thoroughness of the topics in the proposed book. As an editor, Dr. Hayat has assembled a group of well known researchers and clinicians from many parts of the world to write the state-of-the art chapters on breast cancer, including but not limited to the chapters, on computer-assisted diagnosis, familial breast cancer, serum markers in diagnosis, circulating cancer cells before and after treatments, epigenetic markers, metastasis and its detection, validation of biomarkers, immunohistochemistry, invasive cancer and treatments. He has summarized the problems associated with the complexities of research publications which are not easy reading even for many scientists and clinicians. The subject matter is, undoubtedly, complex and formidable for many breast cancer patients. The current consolidated information on breast cancer research is not readily available. The numbers of cancer cases are projected to increase significantly by 2030, especially in low and middle income countries. Even in the advanced countries, there is a population of low and middle income people who do not have access to appropriate diagnosis and treatment. These people suffer from the same problems as those belonging to the low and middle income countries. Dr. Hayat has provided data in his preface showing that some cancers can be reduced by changes in lifestyle and education. His assessment is very timely. With best wishes and regards to Dr. Hayat." Akhouri A. Sinha, Ph.D. Professor of Genetics, Cell Biology and Development, The University of Minnesota and Research Scientist at the Veterans Affairs Medical Center, Minneapolis, Minnesota. "Professor Hayat has done it again! He has edited (METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS, to be published by Springer) a comprehensive treatise on diagnosis, therapy, recurrence, resistance along with risk benefit ratio in cancers with special emphasis on breast cancer. Scientists and clinicians from the world over have contributed the latest advances in their respective areas of expertise. The reader is provided with a whole field view of the state of the art in breast cancer management. This treatise will serve as a must read for oncologists, scientist researchers and students of cancer biology. I look forward to the next series dealing with epidemiology, genetic predisposition and the role of the tumor microenvironment in cancer biology." Debabrata Banerjee Ph.DAssociate ProfessorMedicine and PharmacologyCancer Institute of New Jersey, New Brunswick
Les mer
The only book that discusses cancer diagnosis, therapy, and prognosis together in one volume Discusses the molecular processes that lead to the development and proliferation of cancer cells Includes recent major advances in cancer diagnosis and therapy Supported throughout with illustrations Identifies patients with high likelihood of clinical benefits from a specific treatment
Les mer

Produktdetaljer

ISBN
9781402084416
Publisert
2008-12-01
Utgiver
Vendor
Springer-Verlag New York Inc.
Høyde
260 mm
Bredde
193 mm
Aldersnivå
Professional/practitioner, P, 06
Språk
Product language
Engelsk
Format
Product format
Innbundet

Redaktør